16 articles for SY Han
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
Korea Research Institute of Chemical Technology
Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
Korea Research Institute of Chemical Technology
Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors.
Korea Research Institute of Chemical Technology
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Institute of Science and Technology
Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Korea Research Institute of Chemical Technology
Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.
Institute of Science and Technology
5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Institute of Science and Technology
Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors
TBA
Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
Gwangju Institute of Science and Technology (GIST)
Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases.
Korea Research Institute of Chemical Technology
Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
Gwangju Institute of Science and Technology
Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Gwangju Institute of Science and Technology
The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Gwangju Institute of Science and Technology (Gist)
